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Abstract
Background: Growing evidence suggests that sirtuins, a family of seven distinct NAD-dependent enzymes, are involved in
the regulation of neuronal survival. Indeed, SIRT1 has been reported to protect against neuronal death, while SIRT2
promotes neurodegeneration. The effect of SIRTs 3–7 on the regulation of neuronal survival, if any, has yet to be reported.
Methodology and Principal Findings: We examined the effect of expressing each of the seven SIRT proteins in healthy
cerebellar granule neurons (CGNs) or in neurons induced to die by low potassium (LK) treatment. We report that SIRT1
protects neurons from LK-induced apoptosis, while SIRT2, SIRT3 and SIRT6 induce apoptosis in otherwise healthy neurons.
SIRT5 is generally localized to both the nucleus and cytoplasm of CGNs and exerts a protective effect. In a subset of neurons,
however, SIRT5 localizes to the mitochondria and in this case it promotes neuronal death. Interestingly, the protective effect
of SIRT1 in neurons is not reduced by treatments with nicotinamide or sirtinol, two pharmacological inhibitors of SIRT1.
Neuroprotection was also observed with two separate mutant forms of SIRT1, H363Y and H355A, both of which lack
deacetylase activity. Furthermore, LK-induced neuronal death was not prevented by resveratrol, a pharmacological activator
of SIRT1, at concentrations at which it activates SIRT1. We extended our analysis to HT-22 neuroblastoma cells which can be
induced to die by homocysteic acid treatment. While the effects of most of the SIRT proteins were similar to that observed
in CGNs, SIRT6 was modestly protective against homocysteic acid toxicity in HT-22 cells. SIRT5 was generally localized in the
mitochondria of HT-22 cells and was apoptotic.
Conclusions/Significance: Overall, our study makes three contributions - (a) it represents the first analysis of SIRT3–7 in the
regulation of neuronal survival, (b) it shows that neuroprotection by SIRT1 can be mediated by a novel, non-catalytic
mechanism, and (c) that subcellular localization may be an important determinant in the effect of SIRT5 on neuronal
viability.
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Introduction
Sirtuins are a family of NAD-dependent enzymes homologous
to the yeast Sir2 protein. Overexpression of Sir2 in yeast,
Caenorhabditis elegans and Drosophila increases lifespan by a process
believed to be analogous to caloric restriction. More recent work
has implicated sirtuins in the control of a variety of biological
processes including transcriptional silencing, chromosomal stabil-
ity, cell cycle progression, apoptosis, autophagy, metabolism,
growth suppression, inflammation, and stress response (for recent
reviews, [1–4]). Mammals express seven sirtuins, termed SIRT1–
SIRT7, which are also referred to as class III histone deacetylases
(HDACs). The seven enzymes share a conserved catalytic core
domain of approximately 275 amino acids but differ in their
amino and carboxyl terminal protein sequences flanking this core.
Moreover, while SIRT1, SIRT2, SIRT3, and SIRT5 deacetylate
histone and non-histone protein substrates, SIRT4 and SIRT6 are
primarily mono-ADP-ribosyl transferases [5–7]. An activity for
SIRT7 has yet to be firmly established. The sirtuins also show
differences in their subcellular localization. SIRT1, which has
highest sequence similarity to yeast Sir2, is largely nuclear where it
deacetylates histones H3 and H4 as well as transcription factors
such as NF-kB, p53, FOXO, Ku70, and PGC-1a (reviewed in [1];
[8]). Although generally described to be a nuclear protein, a few
recent studies have described nucleo-cytoplasmic shuttling of
SIRT1 in response to oxidative stress [8–10]. More recently novel
co-activators of SIRT1 such as AROS and HIC1 and a co-
repressor, DBC1, have also been identified that promote and
inhibit SIRT1-mediated deacetylation of its targets [11–14].
SIRT2 resides mostly in the cytoplasm where it associates with
microtubules and deacetylates a -tubulin [5,15]. When the nuclear
envelope disassembles during mitosis, however, SIRT2 can also
deacetylate histone H4 [16]. SIRT3, SIRT4, and SIRT5 localize
to the mitochondria and are therefore thought to play a role in
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4090energy metabolism and responses to oxidative stress [17]. Within
the mitochondria, these SIRTs appear to localize to different sub-
compartments, suggesting distinct functions [18]. Like SIRT1,
SIRT6 and SIRT7 are nuclear proteins although the three
proteins display distinct sub-nuclear localization patterns; SIRT6
associates with heterochromatin, SIRT7 localizes to nucleoli,
whereas SIRT1 is largely associated with euchromatin within the
nucleus [17].
A growing body of evidence implicates SIRT1 and SIRT2 as
important regulators of neurodegeneration [4,19]. For example,
the overexpression of SIRT1 prevents neuronal death in tissue
culture models of Alzheimer’s disease, amyotropic lateral sclerosis,
and polyglutamine toxicity and reduces hippocampal degeneration
in a mouse model of Alzheimer’s disease toxicity [14,20].
Moreover, treatment with resveratrol, a polyphenolic compound
frequently used as a pharmacological activator of SIRT1, is
protective in a variety of experimental paradigms of neurodegen-
eration (reviewed in [21]). Activation of SIRT1 using other non-
commercially available compounds has also been reported to be
neuroprotective in a model of optic neuritis [22]. On the other
hand, SIRT2 has been reported to promote neuronal death.
Pharmacological and genetic inhibition of SIRT2 protects neurons
against a-synuclein toxicity in vitro as well as in flies [23]. Nothing
has been reported about whether the other five sirtuin proteins
(SIRTs 3–7) can influence the survival or death of neurons.
The goal of our study was to gain insight into the roles of
different sirtuin proteins in the regulation of neuronal survival. To
facilitate a direct comparison of their effects on neuronal viability,
we initially utilized a single and well-established paradigm for our
study – cultured CGNs. These neurons survive well in medium
containing depolarizing levels of potassium but undergo apoptosis
in low potassium medium [24]. We report that SIRT1 and SIRT5
protect CGNs from LK-induced apoptosis, while SIRT2, SIRT3
and SIRT6 promote cell death. To investigate whether these
effects were also seen in response to other apoptotic stimuli and in
other cell types, we subsequently extended our studies to another
paradigm of neuronal apoptosis in which HT-22 neuroblastoma
cells were induced to die by homocysteic acid treatment [25,26].
While the effects of a majority of the SIRT proteins were similar to
that observed in CGNs, in HT-22 cells SIRT5 was found to be
apoptotic while SIRT6 had a mildly protective effect.
Results
Effects of sirtuin expression on neuronal survival
Cultured CGNs undergo apoptosis when switched from
medium containing depolarizing levels of potassium (high
potassium or HK medium) to medium containing non-depolar-
izing levels of potassium (low potassium or LK medium) [24]. We
used this tissue culture paradigm to look at the effect of forced
expression of each of the seven sirtuin proteins on neuronal
survival or death. As shown in Fig. 1A, overexpression of SIRT1
had no effect on neuronal survival in HK, but completely inhibited
LK-induced cell death. Although generally present in the nucleus,
nucleo-cytoplasmic shuttling of SIRT1 has recently been described
[8,27]. In CGNs, ectopically-expressed SIRT1 localizes to the
nucleus in both HK and LK conditions (Fig. 2A). Although the
effect of SIRT1 expression has not been previously studied in
CGNs, our result is consistent with the neuroprotective action of
this sirtuin observed in other cell culture and in vivo experimental
models of neurodegeneration [14,20]. Neuroprotection was also
observed with SIRT1 conjugated to an N-terminus HA-tag ruling
out the possibility that the Flag–tag itself contributed to its
protective efficacy (Fig. 1B). We also expressed a truncated version
of SIRT1 lacking the first 81 amino acids (Trunc-SIRT1-Flag), but
which has been found to retain its catalytic activity [5]. Previous
studies have suggested that the N-terminus region of SIRT1 is
involved in interaction with other proteins and contains two
potential phosphorylation sites (Ser27 and Ser47; [28,29]). Trunc-
SIRT1-Flag was as effective as the full-length form in inhibiting
neuronal death (Fig. 1B).
Pharmacological and genetic inhibition of SIRT2 has been
shown to protect against a-synuclein toxicity in cultured neurons
and in Drosophila suggesting that SIRT2 is involved in promoting
neurodegeneration [30]. Consistent with these findings, SIRT2
overexpression reduces survival of otherwise healthy neurons
(Fig. 1A). In other cell types, SIRT2 is generally cytoplasmic but
translocates to the nucleus during mitosis [16]. We observed that
SIRT2 displays a cytoplasmic localization in CGNs which is not
altered during apoptosis (Fig. 2A).
The overexpression of SIRT3 in CGNs induces death in HK
and increases the extent of cell death in LK medium (Fig. 1A). As
observed previously, SIRT3 localizes to mitochondria in these
neurons (Fig. 2B) [17]. Overexpression of SIRT4 had no effect on
neuronal viability in either HK or LK medium (Fig. 1A). Like
SIRT3, and as previously reported [17], the localization of SIRT4
in CGNs is mitochondrial (Fig. 2B).
SIRT5 overexpression inhibits LK-induced apoptosis (Fig. 1A). In
contrast to previous studies in which SIRT5 expression was restricted
to mitochondria of non-neuronal cell types [17], in a majority of
CGNs SIRT5 is widely distributed displaying nuclear, cytoplasmic
and mitochondrial localization (Fig. 2C). In a small proportion of
these neurons, however, SIRT5 localized solely in mitochondria
(Fig. 2C). An analysis of the relationship between subcellular
localization and neuroprotection reveals that SIRT5 is protective
when it localizes to the cytoplasm. In contrast, when localized to the
mitochondria, SIRT5 promotes apoptosis (Fig. 1C).
Overexpression of SIRT6 promotes neuronal apoptosis, while
SIRT7 has no effect on cell viability in HK or LK medium (Fig 1A).
As observed by other investigators in non-neuronal cells, both of
these proteins localize predominantly to the nucleus (Fig. 2A).
Pharmacological modulators of SIRT1 activity have no
effect on neuroprotection
Several investigators have found that the anti-apoptotic effect of
SIRT1 overexpression in neurons as well as non-neuronal cell
types is mimicked by chemical agonists of SIRT1 and can be
inhibited by pharmacological inhibitors of this sirtuin [11,31–36].
In these paradigms therefore, the effect of SIRT1 is mediated by
its enzymatic activity. To examine whether this was also the case
in CGNs, we examined whether nicotinamide could block the
protective effect of SIRT1 against LK-induced neuronal death.
Nicotinamide is an end-product inhibitor that suppresses the
activity of all sirtuins by directly binding within a conserved pocket
of the enzyme and inhibiting NAD+ hydrolysis [37–39]. It is
widely used as a sirtuin inhibitor in cell culture studies and
nicotinamide’s ability to block SIRT1 activity both in vitro and in
cultured cells has previously been established [5,10,37,40–42].
Surprisingly, nicotinamide fails to reduce the neuroprotective
activity of SIRT1 in CGNs (Fig. 3A). Another more selective and
potent pharmacological inhibitor of SIRT1 is sirtinol [30,43–45].
As seen in Figure 3B, sirtinol had no effect on SIRT1-mediated
neuronal survival. We also used splitomicin, a recently developed
sirtuin inhibitor [46,47]. Like nicotinamide and sirtinol, treatment
of neurons with splitomicin failed to block neuroprotection by
SIRT1 in LK (data not shown).
Resveratrol is a potent pharmacological agonist of SIRT1 [48].
Treatment with this polyphenol induces deacetylation of known
Neuroprotection by Sirtuins
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mimic the anti-apoptotic and anti-tumor activity of SIRT1
[21,48–51]. It has been shown that resveratrol activates SIRT1
and recapitulates its biological effects in cultured cells at 10 uM
[52–56]. As shown in Fig. 3C and as previously reported by Alvira
et al. (2007), treatment with resveratrol at doses of up to 30 mM
did not prevent LK-mediated death of neurons. Our results from
pharmacological activation and inhibition of SIRT1 suggest that
SIRT1-mediated neuroprotection is independent of its deacetylase
activity in CGNs.
Mutant forms of SIRT1 lacking deacetylase activity are
completely neuroprotective
To directly test the possibility that neuroprotection by SIRT1
was not dependent on its catalytic activity, we used a point-mutant
form of SIRT1-H363Y which is catalytically inactive [14,40,57].
Figure 4 shows that this catalytically-inactive form of SIRT1 was
as protective as the wild-type form when overexpressed in neurons.
Complete neuroprotection was also observed with SIRT1-H355A,
another catalytically-dead mutant form of SIRT1 that is
commonly used (Fig. 4) [9,58–60]. Taken together with the failure
of SIRT1 inhibitors to reduce neuroprotection, this result confirms
that the deacetylase activity of SIRT1 is not required for
neuroprotection in CGNs.
Forced sirtuin expression in the HT-22 mouse
neuroblastoma cell line. We next examined whether the
effects observed with SIRT1, SIRT2, SIRT3, SIRT5, and SIRT6
on the regulation of LK-induced neuronal death extended to
mouse HT-22 cells, a hippocampally-derived neuroblastoma cell
line. HT-22 cells grow robustly in serum-containing medium but
undergo apoptosis when maintained in serum-free medium.
Apoptosis is also induced in these cells following treatment with
homocysteic acid (HCA), a glutathione-depleting drug that causes
oxidative stress [25,26,61]. We examined the effect of expressing
each of the five SIRT proteins in HT-22 cells maintained in
normal serum medium, treated with serum-free medium or treated
with HCA. As shown in Fig. 5A, SIRT1 protects against HCA-
induced and serum withdraw-induced apoptosis indicating that its
protective action is versatile. Recent reports have described that
SIRT1 shuttles to the cytoplasm upon oxidative stress rendering it
incapable of exerting its inactivating effect on anti-apoptotic
substrates within the nucleus and consequently sensitizing cells to
Figure 1. Effect of SIRT 1–7 expression on neuronal survival. (A) Sirtuin family expression and cerebellar granule neuron survival. Expression
plasmids encoding Flag-tagged forms of SIRT 1–7 were transfected into CGNs and the cultures were switched to HK or LK medium. The proportion of
transfected neurons that were apoptotic was quantified 24 hrs after the switch and compared with control cultures which were transfected with
CMV-GFP. Viability for transfected cells was determined using DAPI staining of chromatin (*indicates p,.05 compared with GFP HK (control); #
indicates p,.05 compared with GFP LK). (B) Expression of other SIRT1 constructs in neurons confirms neuroprotection. Neurons were transfected
with Flag-SIRT1 (tag on the N-terminus), HA-SIRT1, or Trunc-SIRT1-Flag and switched to HK or LK medium. The proportion of transfected neurons that
were apoptotic was quantified 24 hrs after the switch and compared with control cultures which were transfected with CMV-GFP. Apoptosis was
determined for transfected cells using DAPI staining (* indicates p,.05 compared with GFP LK; control=GFP HK). (C) SIRT5 localization and CGNs
survival. SIRT5 localization in CGNs was determined by immunocytochemistry following SIRT5-Flag transfection and viability assessed using DAPI
staining 24 after HK and LK treatment. The localization of viable and apoptotic SIRT5-Flag expressing cells was scored as nuclear and cytoplasmic or
mitochondrial (* indicates p,.05 compared with nuclear-cytoplasmic).
doi:10.1371/journal.pone.0004090.g001
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neuroblastoma cells however, SIRT1 is in the nucleus even
following HCA-induced oxidative stress (Fig. 5B). As observed in
CGNs, SIRT2 overexpression had an apoptotic effect on
untreated neuroblastoma cells. However, SIRT2 did not
enhance serum deprivation or HCA-induced cell death (Fig. 5A).
As observed in neurons and in other cell types, SIRT2 was
observed exclusively in the cytoplasm of HT-22 cells (Fig. 5B). In
contrast to its generally protective action in CGNs, SIRT5
expression induces apoptosis in otherwise healthy neuroblastoma
cells and also exacerbates the toxic effect of HCA. Also in contrast
to CGNs in which SIRT5 was generally not restricted to the
mitochondria, we find that SIRT5 colocalizes with the
mitochondrial marker Cox4 in HT-22 cells (Fig. 5B). Such a
mitochondrial pattern of localization has been described for
SIRT5 previously [17]. Expression of SIRT3 promotes apoptosis
in neuroblastoma cells and enhances HCA lethality, whereas
SIRT6 does not induce HT-22 cell death (Fig. 5A). In fact, SIRT6
exhibits a modest protective effect against HCA treatment
contrary to its toxic role in the CGN apoptosis paradigm used
in this study. Both SIRT3 and SIRT6 exhibit localization patterns
similar to those seen in CGNs and consistent with previous reports
in other cell types (Fig. 5B) [17].
Discussion
Emerging evidence suggests that sirtuins are involved in the
regulation of neuronal survival and death. The overall consensus
Figure 2. Subcellular localization pattern of SIRT 1–7 in neurons. Expression plasmids encoding Flag-tagged forms of SIRT 1–7 were
transfected into CGNs and the cultures were switched to HK or LK medium. The localization of each sirtuin was visualized by immunocytochemistry
using a Flag antibody. DAPI staining was used to label the nucleus. In some cases, Cox4 antibody was used to visualize mitochondria. Images were
obtained with a Nikon Eclipse 80i using a 606objective. (A) Subcellular localization of SIRT1, SIRT2, SIRT6, and SIRT7 in HK and LK-treated neuronal
cultures. Non-apoptotic cells were used for SIRT2 and SIRT6 in HK to show localization. (B) Mitochondrial localization of SIRT3 and SIRT4. The punctate
pattern of SIRT3 and SIRT4 correspond to mitochondrial localization as evidenced by the overlap with Cox4 immunostaining. (C) Subcellular
localization of SIRT5 in CGNs. In HK treatment SIRT5 predominately localizes to the cytoplasm, mitochondria, and nucleus (HK panel) while in LK SIRT5
can localize to the cytoplasm, mitochondria, and nucleus (upper LK panel) or to mitochondria (lower LK panel). Mitochondrial localization of SIRT5 is
associated with apoptosis.
doi:10.1371/journal.pone.0004090.g002
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is mediated by deacetylation of molecules such as p53 and PGC-
1a [10,22]. In contrast, SIRT2 has been reported to promote
neurodegeneration in experimental models of Parkinson’s disease
[23]. In this study we examined the influence of all seven members
of this sub-family of HDAC proteins on the survival of CGNs. It is
noteworthy that the activities of SIRTs 3–7 have not been
previously studied in the context of neuronal survival. We report
for the first time that SIRT5 has neuroprotective activity, while
SIRT3 and SIRT6 are neurotoxic when overexpressed in neurons.
With the exception of SIRT5, the subcellular localization pattern
of these sirtuin proteins in CGNs is as previously reported in non-
neuronal cell types. Whereas SIRT5 is strictly mitochondrial in
other cells types, in CGNs it is generally present in the cytoplasm,
nucleus and mitochondria with only a small proportion of cells
displaying selective mitochondrial localization. We find that when
localized to the mitochondria the protective activity of SIRT5 is
replaced by a pro-apoptotic effect. More work is necessary to
delineate what factors and mechanisms determine the localization
of SIRT5 within cells.
Figure 3. Pharmacological modulators of SIRT1 activity have no effect on neuroprotection. (A) Neurons treated with nicotinamide. CGNs
were transfected with Flag-tagged SIRT1 or GFP control vector and the cultures switched to LK medium or LK-medium supplemented with 5 mM
nicotinamide. Viability of transfected neurons (detected by Flag immunocytochemistry) was quantified 24 hours later (* indicates p,.05 compared
with GFP LK; # indicates p,.05 compared with GFP HK). (B) Sirtinol does not affect SIRT1 protection. Flag-tagged SIRT1 and GFP vectors were
transfected into CGNs. The neurons were then treated with LK medium or LK-medium supplemented with 100 mM sirtinol. Survival for SIRT1-
transfected neurons was assessed using immunocytochemistry and DAPI staining 24 hours following treatment (* indicates p,.05 compared with
GFP LK; # indicates p,.05 compared with GFP HK). (C) Resveratrol cannot rescue neurons in LK. Cultured CGNs were switched to HK medium, LK
medium, or LK medium containing 10 or 30 mM resveratrol. Neuronal viability was quantified 24 hours later by DAPI staining.
doi:10.1371/journal.pone.0004090.g003
Figure 4. A deacetylase-deficient form of SIRT1 is neuropro-
tective. CGNs were transfected with vectors encoding GFP, Flag-
tagged wild-type form of SIRT1, or the deacetylase-dead mutation
forms of SIRT1, H363Y or H355A. The cultures were then switched to HK
or LK medium for 24 hours and viability of transfected neurons was
quantified by DAPI staining (* indicates p,.05 compared with GFP LK).
doi:10.1371/journal.pone.0004090.g004
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CGNs have similar effects in another model of neuronal apoptosis,
we used hippocampus-derived HT-22 neuroblastoma cells. While
the anti- and pro-survival effects of SIRT1, SIRT2, and SIRT3
were preserved in HT-22 cells, there were differences in the cases
of SIRT5 and SIRT6. Expression of SIRT5, which is generally
protective in CGNs, is apoptotic in HT22 cells and potentiates the
level of cell death induced by HCA treatment or serum
withdrawal. In CGNs protection by SIRT5 is associated with a
non-mitochondrial subcellular localization. In fact, neuronal
viability is low when this protein is localized to mitochondria. In
HT-22 neuroblastoma cells, SIRT5 is almost always mitochon-
drially-associated (Fig. 5B). These observations suggest that the
opposing action of SIRT5 on neuronal viability is likely to be
dictated by its subcellular localization. In the case of SIRT6, the
pro-apoptotic action seen in CGNs is not observed in HT-22 cells
although its subcellular localization pattern is the same in both cell
types. This result suggests that differences in intracellular context
or protein-protein interactions may determine activity of SIRT6
with respect to the regulation of apoptosis.
All biological effects of sirtuins have so far been attributed to their
enzymatic activity. Intensive effort is being spent on identifying small-
molecule pharmacological modulators of sirtuin activity as therapeu-
tic tools to treat neurodegenerative diseases as well as other age-
related disorders such as type 2 diabetes, cancer, inflammation and
cardiovascular disease (reviewed in [1]; [3,4,21]). An interesting and
novel finding of our study is that the neuroprotection by SIRT1 is not
affected by nicotinamide, a potent and noncompetitive inhibitor of
the sirtuins. Sirtinol, a pharmacological inhibitor of SIRT1 with a
distinct mechanism of action, also fails to reduce neuroprotection by
SIRT1. Other investigators have established the selectivity and
potency of sirtinol as a selective SIRT1 inhibitor by showing that its
biological effects are faithfully mimicked by SIRT1 siRNA and that it
can neutralize the actions of pharmacological SIRT1 activators [22].
We also find that resveratrol, a commonly-used agonist of SIRT1 as
well as other sirtuins, does not protect neurons against LK-induced
neuronal death. This finding is consistent with the results of Alvira et
al., 2007 who also failed to observe protection with resveratrol in LK-
treated CGNs [35]. Most convincingly, we find that two separate
point-mutant forms of SIRT1, H363Y and H355A, are both as
protective as wild-type SIRT1 in CGNs. Previous work by a number
of other laboratories has established that both of these two mutant
forms of SIRT1 have no detectable deacetylase activity in vitro or in
transfected cells [9,14,57–60,62]. SIRT1 also has weak ADP-
ribosyltransferase activity [63]. This ADP-ribosyltransferase activity
is required for the interaction of SIRT1 with PGC1a, but not its
interaction with with p53 or Foxo3a [42]. We have used a mutant
SIRT construct, SIRT1-G261A which lacks ADP-ribosyltransferase
activity [42] and found that its overexpression is fully protective
against LK-induced neuronal death (Ma and D’Mello, unpublished
observation). Our results therefore suggest a novel, non-catalytic
mechanism of action for SIRT1-mediated neuroprotection. Further
effort will be necessary to define what this mechanism is but one
possibility is that it involves interactions between SIRT1 and other
apoptosis-regulatory proteins. Association between SIRT1 and p53,
p65, c-jun and E2F1, all of which are involved in regulating neuronal
apoptosis, has previously been reported (reviewed in [1]; [55,64–66]).
An obvious caveat of our study is that it relies solely on
ectopically-expressed proteins. It is likely that overexpression
represents an amplification of the normal activity of these proteins
on neuronal survival. But it is also possible that the effects we
observe represent an artifact of overexpression and as such have
little physiological relevance. Further investigation using siRNA-
mediated suppression of endogenous sirtuins or utilization of
cultures from knock-out mice lacking individual sirtuins will be
necessary to study this issue. Besides physiological relevance
however, our finding that SIRT1 and SIRT5 are neuroprotective
when expressed at elevated levels raises the possibility that
Figure 5. Forced sirtuin expression in the HT-22 cells. (A) Effect of sirtuin expression on HT-22 cell survival. Sirtuin expression levels were
enhanced in HT-22 neuroblastoma cells via transfection with mammalian expression plasmids. HT-22 cells were treated 24 hours following
transfection with normal growth medium (untreated), 1 mM HCA or Serum-free (SF) medium for 24 hours. The viability of transfected cells was
determined using a TUNEL assay. The mean of 5 experiments were taken (* indicates p,.05 compared with Flag untreated sample; # indicates p,.05
compared with Flag HCA sample; ^ indicates p,.05 compared with Flag SF sample). (B) Subcellular localization of exogenous SIRT1, SIRT2, SIRT3,
SIRT5 and SIRT6 in HT-22 cells. HT-22 cells were transfected with SIRT-Flag constructs and immunocytochemistry performed using a Flag antibody.
DAPI staining was used to visualize nuclei/chromatin. SIRT5 shows colocalization with the mitochondrial protein Cox4.
doi:10.1371/journal.pone.0004090.g005
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vulnerable neuronal populations pharmacologically, or ectopically
expressing them at high levels (using viral vectors for example)
could represent viable therapeutic approaches to prevent neuronal
loss in neurodegenerative diseases.
In conclusion, our study represents the first investigation of the
effects of SIRTs 3–7 on the regulation of neuronal survival.
Moreover, we show for the first time that in addition to inhibiting
cell death by deacetylating apoptosis-regulatory proteins, SIRT1
can act through a novel, catalytic-independent mechanism to
protect against apoptosis. And finally, we show that SIRT5 can
have contrasting effects on neuronal viability, which is dictated by
its subcellular localization.
Materials and Methods
Materials
Unless otherwise indicated, all tissue culture reagents and
Lipofectamine 2000 were purchased from Invitrogen (Invitrogen,
Carlsbad, CA). Flag antibody, cytosine arabinofuranoside and
DAPI were from Sigma (St. Louis, MO). Cox4 antibody was from
Santa Cruz Biotechnology(Santa Cruz, CA). Expression plasmids
for Flag-tagged SIRT1–SIRT7, HA-tagged SIRT1, Flag-tagged
SIRT1-H363Y and Flag-tagged SIRT-G261A were purchased
from Addgene (Addgene, Cambridge, MA). Flag-tagged SIRT1-
H355A was provided by Dr. Jiandong Chen (H. Lee Moffitt
Cancer Center, Tampa, FL). All cDNAs were sequenced and the
expression of a protein of the correct size verified following
transfection of HEK293T cells.
Culturing of cerebellar granule neurons and HT-22 cells
Cerebellar granule neurons were cultured from 7–8 day old
Wistar rats (Charles River, Wilmington, MA) as previously
described [24]. The cultures were plated in 24-well poly-L-lysine
coated dishes with glass coverslips at a density of 1610
6 cells/well
in basal Eagle’s medium with Earle’s salts (BME) supplemented
with 10% FBS, 25 mM KCl, 2 mM glutamine and 100 mg/mL
gentamicin. To prevent the proliferation of the small number of
non-neuronal cells, cytosine arabinofuranoside (10 mM) was added
to the culture medium about 20 hrs after plating. HT-22 cells were
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% FBS, penicillin and streptomycin.
Transfection of primary neurons
The neuronal cultures were transfected 4–5 days after plating
using cesium chloride-purified plasmid DNA and the calcium
phosphate method as previously described [67]. 3 mg/mL of
plasmid DNA was used per well. A day after transfection, the cells
were rinsed once and then maintained in serum-free BME
medium containing either 5 mM KCl (low potassium, LK) or
25 mM KCl (high potassium, HK). Control cultures were
transfected with CMV-GFP. Transfected neurons were detected
by GFP fluorescence or by immunostaining using Flag antibody
(for all seven sirtuin proteins). Neuronal viability was quantified by
staining cell nuclei with DAPI as previously described [67,68].
Condensed or fragmented nuclei were scored as apoptotic. Double
staining was performed to determine the subcellular localization of
mitochondrial SIRTs. Ectopically expressed SIRTs were detected
using a Flag antibody and a Cox4 antibody was used to label
mitochondria. For immunocytochemistry, both Flag antibody and
Cox4 antibody were used at 1:200 dilution.
Transfection of HT-22 cells
Cellswereplatedatadensityof1.5610
4cells/wellin24wellplates
in antibiotic-free DMEM medium with 10% FBS. Transfection was
carried out using 1 mg/mL of plasmid DNA and Lipofectamine 2000
according to manufacturer’s instructions. Exogenous genes were
allowed to express for 24 hours at which time the cells were treated
w i t hf r e s hn o r m a lg r o w t hm e d i u m ,1m MH C Ao rD M E Mw i t h o u t
FBS. Approximately 17 hours after treatment the viability of
transfected cells was determined using immunocytochemistry and a
TUNEL assay (Promega, Madison, WI) that detects cleaved DNA
characteristic of apoptotic cells.
Statistics
Graphs represent mean values obtained from three or more
independent experiments. Error bars show standard deviation
from three separate experiments. Statistical analysis for graphical
data was performed using an unpaired t-test (student t-test). P
values of ,0.05 were deemed statistically significant.
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